Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of cefepime-AAI101 vs piperacillin/tazobactam for complicated urinary tract infections
2017-004868-35Phase 3Completed
- Sponsor
- Allecra Therapeutics
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefepime + enmetazobactam in complicated urinary tract infection (cUTI) and pyelonephritis (2 arms), sponsored by Allecra Therapeutics. Primary endpoint: Overall treatment success at test-of-cure in m-MITT population. Started Mar 2018; status: completed.
02
Drugs
cefepime + enmetazobactam
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on 2017-004868-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004868-35.